EFC17801
Brief description of study
The study will investigate the eficacy and safety of belumosudil compared with placebo, administered on top of azithromycin and SOC regimen of immunosuppression in male or female participants at least 1 year after bilateral lung transplant, at least 18 years age and with progressive CLAD despite azithromycin.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
